A New Tool for Monitoring Pharmaceutical Freeze Drying
SP Scientific has published on its website a new white paper that examines the benefits of applying Tunable Diode Laser Absorption Spectroscopy (TDLAS) for monitoring of pharmaceutical freeze drying processes.
The paper discusses how through the combination of TDLAS Near-IR spectroscopic measurements and a well-established heat and mass transfer model describing freeze drying, users can obtain information about key process parameters affecting end product quality.
The white paper provides an informative introduction to the physics behind the TDLAS principle of operation. The authors also describe the application of the technique, using the SP Scientific LyoFlux 200 LyoFlux sensor, to primary and secondary freeze drying endpoint and product temperature determinations. In addition to the determination of process endpoints and product temperatures, the LyoFlux 200 TDLAS sensor can be used to assess freeze dryer equipment capability limits, monitor process and product parameters and also for developing drying cycles based upon Quality by Design procedures.
In summary, the white paper shows how the LyoFlux 200 TDLAS sensor provides a unique measurement capability that provides autonomous and continuous water vapor mass flow determinations throughout the freeze drying process. LyoFlux is therefore applicable to laboratory, pilot and production scale freeze dryers, enabling use of this PAT tool for process scale-up and process control.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.